Structure-Guided Screening for Functionally Selective D2 Dopamine Receptor Ligands from a Virtual Chemical Library.
暂无分享,去创建一个
Harald Hübner | Peter Gmeiner | Jens Carlsson | Alexey A. Zeifman | Mariama Jaiteh | P. Gmeiner | Jens Carlsson | H. Hübner | Mariama Jaiteh | Barbara Männel | Alexey Zeifman | Alena Randakova | Dorothee Möller | Barbara Männel | A. Zeifman | A. Randáková | D. Möller | Alena Randáková
[1] P. Gmeiner,et al. Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates. , 2011, Trends in pharmacological sciences.
[2] R. Lefkowitz,et al. Therapeutic potential of β-arrestin- and G protein-biased agonists. , 2011, Trends in molecular medicine.
[3] Lei Shi,et al. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. , 2012, Journal of medicinal chemistry.
[4] P. Gmeiner,et al. Click chemistry on solid phase: parallel synthesis of N-benzyltriazole carboxamides as super-potent G-protein coupled receptor ligands. , 2006, Journal of combinatorial chemistry.
[5] Maria F. Sassano,et al. Conformation Guides Molecular Efficacy in Docking Screens of Activated β-2 Adrenergic G Protein Coupled Receptor , 2013, ACS chemical biology.
[6] David Rodríguez,et al. Structure-based discovery of selective serotonin 5-HT(1B) receptor ligands. , 2014, Structure.
[7] Ralf C. Kling,et al. Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety. , 2013, Journal of medicinal chemistry.
[8] T. S. Kobilka,et al. Structural Insights into the Dynamic Process of β2-Adrenergic Receptor Signaling , 2015, Cell.
[9] Arthur Christopoulos,et al. Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.
[10] Michael M. Mysinger,et al. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.
[11] Arthur Christopoulos,et al. Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.
[12] Ralf C. Kling,et al. Functionally selective dopamine D₂, D₃ receptor partial agonists. , 2014, Journal of medicinal chemistry.
[13] T. Daigle,et al. Targeting β-arrestin2 in the treatment of l-DOPA–induced dyskinesia in Parkinson’s disease , 2015, Proceedings of the National Academy of Sciences.
[14] Maria F. Sassano,et al. Discovery of β-Arrestin–Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy , 2011, Proceedings of the National Academy of Sciences.
[15] Matthew E Welsch,et al. Privileged scaffolds for library design and drug discovery. , 2010, Current opinion in chemical biology.
[16] David Rodríguez,et al. Molecular Docking Screening Using Agonist-Bound GPCR Structures: Probing the A2A Adenosine Receptor , 2015, J. Chem. Inf. Model..
[17] Kyle V. Butler,et al. Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists. , 2016, Journal of medicinal chemistry.
[18] Ryan G. Coleman,et al. ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..
[19] S. Rasmussen,et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.
[20] R. Lefkowitz,et al. When 7 transmembrane receptors are not G protein-coupled receptors. , 2005, The Journal of clinical investigation.
[21] Robert J. Lefkowitz,et al. A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling , 2007, Proceedings of the National Academy of Sciences.
[22] Maria F. Sassano,et al. Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists. , 2012, Journal of medicinal chemistry.
[23] Arthur Christopoulos,et al. The role of kinetic context in apparent biased agonism at GPCRs , 2016, Nature Communications.
[24] Ruben Abagyan,et al. Structure-Based Ligand Discovery Targeting Orthosteric and Allosteric Pockets of Dopamine Receptors , 2013, Molecular Pharmacology.
[25] A. Christopoulos,et al. Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor. , 2014, Journal of medicinal chemistry.
[26] S. Rasmussen,et al. Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.
[27] M. Ferrer,et al. Discovery and Characterization of a G Protein–Biased Agonist That Inhibits β-Arrestin Recruitment to the D2 Dopamine Receptor , 2014, Molecular Pharmacology.
[28] Ralf C. Kling,et al. Molecular determinants of biased agonism at the dopamine D₂ receptor. , 2015, Journal of medicinal chemistry.
[29] Brian K. Shoichet,et al. Rapid Context-Dependent Ligand Desolvation in Molecular Docking , 2010, J. Chem. Inf. Model..
[30] R. Stevens,et al. Structure-function of the G protein-coupled receptor superfamily. , 2013, Annual review of pharmacology and toxicology.
[31] A. Christopoulos,et al. A structure-activity analysis of biased agonism at the dopamine D2 receptor. , 2013, Journal of medicinal chemistry.
[32] R. Gainetdinov,et al. Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics , 2008, Proceedings of the National Academy of Sciences.
[33] Márton Vass,et al. Multiple fragment docking and linking in primary and secondary pockets of dopamine receptors. , 2014, ACS medicinal chemistry letters.
[34] Chris de Graaf,et al. Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study , 2015, J. Chem. Inf. Model..
[35] L. Bohn,et al. Morphine Side Effects in β-Arrestin 2 Knockout Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.
[36] Henry Lin,et al. Structure-based discovery of opioid analgesics with reduced side effects , 2016, Nature.
[37] Avner Schlessinger,et al. Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.
[38] D. Winpenny,et al. Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonists , 2016, British journal of pharmacology.
[39] C. Alzheimer,et al. Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure. , 2017, Journal of medicinal chemistry.
[40] D. Möller,et al. 1,4-Disubstituted aromatic piperazines with high 5-HT2A/D2 selectivity: Quantitative structure-selectivity investigations, docking, synthesis and biological evaluation. , 2015, Bioorganic & medicinal chemistry.
[41] Jonathan A. Javitch,et al. Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.
[42] R. Rodriguiz,et al. Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice , 2016, Neuropsychopharmacology.
[43] D. Möller,et al. Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D2R Agonists. , 2017, Journal of medicinal chemistry.
[44] Kurt Wüthrich,et al. Biased Signaling Pathways in β2-Adrenergic Receptor Characterized by 19F-NMR , 2012, Science.
[45] David Rodríguez,et al. Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures. , 2015, Current topics in medicinal chemistry.
[46] Harald Hübner,et al. Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding. , 2009, Journal of medicinal chemistry.
[47] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[48] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[49] Arthur Christopoulos,et al. Biased Agonism at G Protein‐Coupled Receptors: The Promise and the Challenges—A Medicinal Chemistry Perspective , 2014, Medicinal research reviews.
[50] Christopher G. Tate,et al. Crystal Structures of a Stabilized β1-Adrenoceptor Bound to the Biased Agonists Bucindolol and Carvedilol , 2012, Structure.